July 15, 2025

Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

Main finding shows the combination of CDK2/4/6 inhibitor PF-06873600 and endocrine therapy is being tested for breast cancer.
A total of 151 patients were included in the safety analysis set to evaluate treatment effects and safety.
Demographics and baseline characteristics were carefully recorded to assess the population’s response to therapy.
These findings could lead to improved treatment options for breast cancer, contributing to advancements in cancer therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Phase I/IIa study reveals safety data for a new CDK2/4/6 inhibitor combined with endocrine therapy in patients with breast cancer.

Yap et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark